主要文件

查看所有文档

R8404

Rufinamide

Name: Rufinamide
Brand: SIGMA

≥98% (HPLC), powder

别名:

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₀H₈F₂N₄O

化学文摘社编号:

106308-44-5

分子量:

238.19

NACRES:

NA.77

PubChem Substance ID:

24724595

UNSPSC Code:

12352200

MDL number:

MFCD00865314

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: 9 mg/mL

originator

Novartis

storage temp.

−20°C

SMILES string

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChI key

POGQSBRIGCQNEG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

说明

General description

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem/physiol Actions

Broad-spectrum anticonvulsant.

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Rufinamide

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H336,H351,H361fd

pcodes

P202 - P261 - P271 - P280 - P304 + P340 + P312 - P308 + P313

Hazard Classifications

Carc. 2 - Repr. 2 - STOT SE 3

target_organs

Central nervous system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development.

K K Jain

Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)

This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12

Rufinamide.

Emma D Deeks et al.

CNS drugs, 20(9), 751-760 (2006-09-07)

Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures

Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.

Paul L McCormack

PharmacoEconomics, 30(3), 247-256 (2012-02-16)

Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy

查看所有相关文献

全球贸易项目编号

货号	GTIN
R8404-10MG	04061832559520
R8404-50MG	04061832559537